This browser is no longer supported

Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.

Annual Reports

View our online annual report 2022


Key Business Performance and Highlights

CSL Growth Icon
  • Remained focused on delivering on our promise to patients and public health during an unprecedented time of uncertainty.
  • US$17.8 million supporting product access across the world.*
  • US$50 million in global community investment across our strategic areas of support.
CSL Growth Icon
  • Research and development (R&D) investment of US$1.16 billion.*
  • Etranacogene dezaparvovec (Haemophilia B gene therapy) primary end point achieved in HOPE-B study with MAA (EU) and BLA (US) submitted.
  • Garadacimab Phase III study enrolment completed for HAE.
  • CSL112 (currently in Phase III for cardiovascular disease) continues to progress with over 80% enrolment.
  • Phase II study for an adjuvanted QIV cell-based influenza vaccine completed.
  • Government funding for new biotech start-up incubator partnership between CSL, WEHI and University of Melbourne.
  • Achieved 24 product registrations or new indications across the globe.
CSL Growth Icon
Efficiency and reliable supply
  • Ongoing investment in major capital projects at all manufacturing sites to support future growth.
  • In 2021/22, 27 new plasma collection centres opened.
  • New plasmapheresis platform approved.
  • Participated in 406 regulatory inspections of our manufacturing facilities and plasma collection centres.*
  • 135 million influenza vaccine doses distributed by CSL Seqirus.
  • Fill and finish capacity expansion projects completed at Holly Springs and Liverpool for influenza vaccines.
CSL Growth Icon
Sustainable growth
  • Revenue up 3% at constant currency.
  • Significant growth in plasma collections.
  • Strong performance by HIZENTRA®, our market leading subcutaneous immunoglobulin product with sales up 20%.
  • KCENTRA®, our peri-operative bleeding product, grew 18% as hospital demand returned to pre-pandemic levels.
  • CSL Seqirus revenue up 13% at constant currency driven by strong growth in seasonal influenza vaccines and product differentiation.
  • US$9.9 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*
  • Announced Science Based Targets initiative aligned emissions reduction targets
CSL Growth Icon
Digital transformation
  • Enhanced CSL Plasma Donor App with new functionality.
  • Progression of the converged enterprise network strategy across the organisation.
  • Initiation of our next generation Donation Management System.
CSL Growth Icon
People and culture
  • Achieved 77.9% employee engagement* score, an increase on the previous year.
  • 44% female representation at Board level, 61% female across the Group.*
  • Established early career programs for STEM talent around the globe to build our future talent pipeline.
  • CSL named among America’s best employers by Forbes magazine and also recognized as one of Australia and New Zealand’s Best Places to Work by The Australian Financial Review.

* Limited assurance by Ernst & Young.

Annual Report Archive


Introduction to CSL

See how we are driven by our promise.

Learn More

Board and Management

View our Board and Management here.

Learn More

Corporate Governance

View our corporate governance here.

Learn More